Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)
March 25, 2024 07:00 ET
|
Nurix Therapeutics, Inc.
Researchers will apply the latest TPD drug discovery technology to target fusion proteins that cause pediatric cancer Cancer Grand Challenges is an initiative funded by Cancer Research UK SAN...
Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting
March 20, 2024 09:40 ET
|
Nurix Therapeutics, Inc.
Disclosure of the discovery and structure of NX-1607, the first inhibitor of CBL-B to advance into clinical studies.
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
March 11, 2024 07:00 ET
|
Nurix Therapeutics, Inc.
Nurix's Phase 1a/1b study of NX-2127 in adults with r/r B-cell malignancies to enroll new patients after partial clinical hold lifted
Nurix Therapeutics to Participate in Upcoming Investor Conferences
March 06, 2024 16:00 ET
|
Nurix Therapeutics, Inc.
Nurix Therapeutics to participate in March investor conferences
Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting
March 05, 2024 16:30 ET
|
Nurix Therapeutics, Inc.
Nurix to present at AACR2024 Annual Meeting
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
February 15, 2024 16:00 ET
|
Nurix Therapeutics, Inc.
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader
February 01, 2024 16:01 ET
|
Nurix Therapeutics, Inc.
Data reveal oncogenic scaffold function of BTK mutations that lack kinase activity and show these mutations remain susceptible to degradation by NX-2127 NX-2127 degrades BTK in patients regardless of...
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL
January 16, 2024 16:01 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases
January 08, 2024 07:00 ET
|
Nurix Therapeutics, Inc.
Positive Phase 1 data presented at American Society of Hematology supports prioritizing the acceleration of enrollment of NX-5948 in leukemia and lymphoma Strategic collaborations in small...
Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 16:01 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...